Brian Abrahams analyst RBC

Currently out of the existing stock ratings of Brian Abrahams, 327 are a HOLD (35.66%), 586 are a BUY (63.9%), 4 are a SELL (0.44%).

Brian Abrahams

Work Performance Price Targets & Ratings Chart

Analyst Brian Abrahams, currently employed at RBC, carries an average stock price target met ratio of 48.61% that have a potential upside of 41.14% achieved within 233 days.

Brian Abrahams’s has documented 1,896 price targets and ratings displayed on 59 stocks. The coverage is on Healthcare, Industrials, Basic Materials, Technology sectors.

Most recent stock forecast was given on APGE, Apogee Therapeutics, Common Stock at 23-Jun-2026.

Wall Street Analyst Brian Abrahams

Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for PTCT (PTC THERAPEUTICS) at 6/18/2018. The price target of $38 was fulfilled within 1 day with a profit of $9.88 (20.63%) receiving and performance score of 206.35.

Average potential price target upside

ATAI ATAI Life Sciences BV BIIB Biogen CELG Celgene DVAX Dynavax Technologies ENTA Enanta Pharmaceuticals ETN Eaton PLC GILD Gilead Sciences GLPG Galapagos NV ADR HOOK Hookipa Pharma ICPT Intercept Pharmaceuticals INCY yte ITCI Intracellular Th KPTI Karyopharm Therapeutics KRTX Karuna Therapeutics MRUS Merus BV NBIX Neurocrine Biosciences OVID Ovid Therapeutics PLRX Pliant Therapeutics  PTCT PTC Therapeutics SAGE Sage Therapeutic SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals CNST Constellation Pharmaceuticals IGMS IGM Biosciences BCRX BioCryst Pharmaceuticals ALDR Alder BioPharmaceuticals MRNS Marinus Pharmaceuticals MTCR Metacrine  XENE Xenon Pharmaceuticals ETNB 89bio PRTA Prothena plc REGN Regeneron Pharmaceuticals NBSE NeuBase Therapeutics ACHN Achillion Pharmaceuticals CRBP Corbus Pharmaceuticals EIGR Eiger Biopharmaceuticals ITMN InterMune MNMD Mind Medicine  MRTX Mirati Ther PTI Proteostasis Therapeutics AMAM Ambrx Biopharma American Depositary Shares AXSM Axsome Therapeutics APLT Applied Therapeutics CTNM Contineum Therapeutics, Common Stock NMRA Neumora Therapeutics ACAD ACADIA Pharmaceuticals MLTX MoonLake Immunotherapeutics RARE Ultragenyx THTX Theratechnologies CDTX Cidara Therapeutics GHRS GH Research PLC NRIX Nurix Therapeutics  KYMR Kymera Therapeutics APGE Apogee Therapeutics, Common Stock CE Celanese CNS Cohen & Steers IT Gartner SA Seabridge Gold PHVS Pharvaris BV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 13-Jul-2021

$15

$9.71 (183.55%)

$14

2 months 18 days ago
(20-Apr-2026)

0/6 (0%)

$10.1 (206.12%)

Buy Since 19-Oct-2021

3 months 21 days ago
(17-Mar-2026)

0/8 (0%)

$9.51 (173.22%)

Buy Since 09-Mar-2026

$14

$8.71 (164.65%)

$12

3 months 29 days ago
(09-Mar-2026)

0/2 (0%)

$10.11 (259.90%)

Buy Since 29-Jul-2025

$16

$10.71 (202.46%)

$14

11 months 7 days ago
(01-Aug-2025)

0/2 (0%)

$11.83 (283.69%)

Buy Since 08-Jul-2021

$8

$2.71 (51.23%)

$7

1 years 6 days ago
(02-Jul-2025)

1/3 (33.33%)

$5.25 (190.91%)

120

Show more analysts

Please expand the browser size to see the chart

Which stock is Brian Abrahams is most bullish on?

Potential upside of $107.73 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Brian Abrahams is most reserved on?

Potential downside of -$24.86 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Brian Abrahams?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?